RETATRUTIDE
60mgRETATRUTIDE60mg
Retatrutide (LY3437943) 60mg is a next-generation triple agonist peptide targeting GIP, GLP-1, and Glucagon receptors simultaneously. >98.6% HPLC purity. Research use only.
Key Benefits
- Triple receptor agonist — GIP + GLP-1 + Glucagon
- 24.2% body weight loss in Phase 2 (highest ever recorded)
- Up to 86% liver fat reduction
- >98.6% HPLC purity with Certificate of Analysis
- Increases energy expenditure via glucagon pathway
- Once-weekly administration
Contact Us for Pricing
Get competitive wholesale pricing for RETATRUTIDE 60mg. Our team is available 24/7.
Direct line: +44 7429 917553
Licensed Supplier
Authorized pharmaceutical distributor
100% Original
Guaranteed authentic products
Worldwide Delivery
International shipping available
24/7 Support
WhatsApp support anytime
How RETATRUTIDE Works
Retatrutide simultaneously activates three metabolic receptors: (1) GIP receptor — enhances insulin secretion and fat metabolism, (2) GLP-1 receptor — reduces appetite and slows gastric emptying, (3) Glucagon receptor — increases energy expenditure and hepatic fat oxidation. This triple mechanism creates synergistic effects on weight loss, glycemic control, and liver fat reduction that surpass single and dual agonist approaches.
About RETATRUTIDE 60mg
Retatrutide (LY3437943) 60mg lyophilized peptide is Eli Lilly's investigational triple receptor agonist — the first molecule to simultaneously activate GIP, GLP-1, and Glucagon receptors. In Phase 2 clinical trials, Retatrutide demonstrated unprecedented 24.2% body weight loss at 48 weeks, surpassing all existing GLP-1 and dual agonist therapies. The addition of glucagon receptor agonism — absent from both semaglutide (GLP-1 only) and tirzepatide (GIP + GLP-1) — increases energy expenditure and promotes hepatic fat oxidation, achieving up to 86% liver fat reduction in participants with metabolic dysfunction-associated steatotic liver disease (MASLD). Our Retatrutide is research-grade with >98.6% purity verified by HPLC. Each vial includes a Certificate of Analysis (CoA) with mass spectrometry, amino acid analysis, and endotoxin testing. Supplied as lyophilized powder for reconstitution with bacteriostatic water.
Common Uses
- Research into triple agonist metabolic pharmacology
- Weight loss mechanism studies
- Metabolic syndrome research
- MASLD/NASH liver fat research
- GIP/GLP-1/Glucagon receptor interaction studies
Dosage Information
Research peptide — 60mg lyophilized powder per vial. In Eli Lilly Phase 2 trials: subcutaneous injection once weekly, dose titration from 1mg to 12mg over 4-week intervals. Not for human consumption without clinical oversight.
Always consult with a qualified healthcare professional for proper dosing. This information is for reference only.
Storage & Handling
Lyophilized form: -20°C long-term (24 months), 2-8°C short-term (12 months). Reconstituted: 2-8°C, use within 30 days. Do not freeze reconstituted solution. Protect from light.
We ensure proper cold chain handling during shipping to maintain product integrity.
Frequently Asked Questions About RETATRUTIDE
Find answers to common questions about ordering, pricing, and shipping.
Related Weight Loss & Diabetes Products
Explore more weight loss & diabetes medications from our catalog
